Cancer Therapy

Preliminary data reported on needle-cryotherapy technology for prostate cancer

Published in Cancer Weekly, November 11th, 2003

The developer of a minimally invasive prostate-cancer-treatment product, ONCURA, said it welcomed the publication of a prospective, multicenter clinical study that evaluates the use of their third-generation, ultrathin needle cryotherapy technology.

"This study demonstrates that ONCURA's unique third-generation equipment is safe, well tolerated, and minimally invasive, with excellent cancer control. Our ongoing multicenter trial will continue to investigate the long-term efficacy of this technique," said Arie Beldegrun, professor of urology, chief of urologic oncology at the David Geffen School of Medicine at UCLA, Los Angeles, California, and the lead investigator of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry